Why Patients Switch & How Much They Save
Wegovy Mounjaro Switching: The Complete Cost Analysis
Switching between Wegovy and Mounjaro has become increasingly common as patients seek the most cost-effective weight management solution. Wegovy contains semaglutide (a GLP-1 receptor agonist), whilst Mounjaro contains tirzepatide (a dual GIP and GLP-1 receptor agonist). Many patients find significant savings when switching to Wegovy, particularly at maintenance doses where our 2.4mg pens cost £209.99 compared to Mounjaro's higher pricing elsewhere. The switching process requires careful dose conversion guidance from a qualified prescriber, as the medications have different potency profiles.
At EverydayMeds (GPhC #9012878), we've streamlined the Wegovy Mounjaro transition process by stocking both medications and providing expert clinical support. Our prescribers understand the approximate dose equivalences and can recommend appropriate starting doses when switching. New customers switching to Wegovy can use code FIRST40, whilst returning customers benefit from code DOSE25 — both applied at checkout to reach our competitive final prices. This dual-medication approach means you won't need to change pharmacy when exploring different GLP-1 options.
Wegovy Mounjaro Pricing Comparison: Where You'll Save
The cost difference between Wegovy and Mounjaro becomes particularly significant at higher doses, where many patients see the greatest potential savings. Our Wegovy pricing structure starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. These prices include our discount codes FIRST40 (new customers) and DOSE25 (returning customers) applied at checkout, representing the final amount you'll pay. For patients requiring long-term treatment, our Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99.
Bundle options provide additional convenience for patients switching to Wegovy from Mounjaro, eliminating the need for multiple orders during dose escalation. Our Progress Trio (0.5mg, 1mg & 1.7mg) costs £369.99 and covers three critical escalation steps, whilst the Intro Trio (0.25mg, 0.5mg & 1mg) costs £299.99 for patients starting fresh. These bundles ensure Reliable Supply continuity — particularly important when switching medications and wanting to avoid any treatment gaps.
Clinical Evidence Behind Wegovy Mounjaro Switching Decisions
The clinical evidence supporting both Wegovy and Mounjaro comes from robust phase 3 trials, though direct head-to-head comparisons remain limited. Wegovy's STEP trial programme demonstrated that patients taking semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, adding another dimension to treatment decisions.
When patients consider switching between Wegovy and Mounjaro, prescribers evaluate individual response patterns, side effect profiles, and cost considerations. Some patients find better tolerability with one medication over another, whilst others prioritise the storage convenience or injection frequency. Both are prescription-only medicines requiring ongoing medical supervision, and switching decisions should always involve clinical assessment rather than cost alone.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of a natural hormone called glucagon-like peptide-1. This hormone is normally released by your intestines after eating and signals to your brain that you're full. Semaglutide may help reduce appetite and promote feelings of satiety after smaller meals, potentially making it easier to maintain a reduced-calorie diet. The medication works on appetite centres in the brain, which may explain why many patients report reduced food cravings and less preoccupation with eating. Unlike Mounjaro's dual mechanism, Wegovy focuses specifically on GLP-1 pathways, providing a well-established approach to weight management that has been extensively studied in clinical trials.
Ordering Your Wegovy Mounjaro Switch Through EverydayMeds
Switching to Wegovy through EverydayMeds begins with our streamlined 3-minute online clinical assessment, designed to capture your medical history, current medications, and previous GLP-1 experience. Our qualified prescribers review each assessment within 3 working days (or 24 hours with express service), paying particular attention to patients switching from Mounjaro to ensure appropriate dose selection. Once approved, your Wegovy pen ships via next-day delivery using our cold-chain, temperature-controlled logistics to maintain medication integrity. The entire process from assessment to delivery typically takes 4-5 days for standard reviews, ensuring minimal treatment gaps during your transition. Our customer service team can coordinate timing to align with your current Mounjaro supply, preventing any overlap or gaps in treatment.
Storage Advantages: Why Wegovy Beats Mounjaro for Travel
One often-overlooked advantage when switching from Mounjaro to Wegovy involves storage flexibility, particularly for patients who travel frequently. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This makes Wegovy significantly more convenient for extended trips, business travel, or situations where refrigeration access might be limited. The FlexTouch pen design provides reliable dose delivery and includes a dose counter to track your progress through the escalation schedule. Proper storage ensures medication potency throughout the treatment period, making this practical advantage meaningful for active lifestyles.
Wegovy Mounjaro Dose Conversion: Clinical Switching Protocols
Converting from Mounjaro to Wegovy requires careful consideration of dose equivalencies, as the medications have different potency profiles and mechanisms of action. Generally, patients switching from Mounjaro may start Wegovy at a dose that reflects their previous tolerance level, though this always requires prescriber assessment. Some patients transitioning from higher Mounjaro doses might begin Wegovy at 0.5mg rather than the standard 0.25mg starter dose, whilst others benefit from the full escalation schedule regardless of previous experience. The transition typically involves a washout period as advised by your prescriber, ensuring the previous medication clears your system appropriately.
Our clinical team at EverydayMeds has extensive experience managing Wegovy Mounjaro transitions and can provide personalised switching recommendations. The assessment process considers your previous dose, response pattern, side effect experience, and individual tolerance factors. This individualised approach helps optimise your switching experience whilst maintaining the safety profile that makes these medications suitable for long-term weight management support.
Complete Your Wegovy Mounjaro Switch Today
Ready to explore switching to Wegovy and potentially save £50+ on your weight management treatment? Our streamlined ordering process makes the transition straightforward, with both FIRST40 and DOSE25 discount codes available at checkout to reach our competitive final prices. Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover which Wegovy dose or bundle suits your switching needs. Our prescribers are standing by to review your assessment and provide personalised switching guidance. With our comprehensive stock of both Wegovy and Mounjaro, you're choosing a pharmacy partner that understands GLP-1 medications and can support your long-term weight management journey. Start your assessment today and join thousands of patients who've successfully switched to save money without compromising on quality care.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
